![]() ![]() Takeda also does most of its business in Japan, where regulators are pushing for cheaper generic drugs as the population ages rapidly. The company makes drugs that treat cancer, but its pipeline of new products is thin. Michelle Gass: The Kohl’s CEO embraced AmazonĪlthough its recent earnings have been strong, Takeda could face tough times ahead.Atul Gawande: The surgeon who Buffett, Bezos and Dimon trust to fix health care.(Takeda declined to make Weber available for an interview for this story.) “It’s really part of this long-term aspiration to be a global player,” he said during a December panel discussion in New York. Weber argues the Shire takeover was necessary to transform Takeda into a major force in the global pharma market. Even Masa Son, the acquisitive head of SoftBank and probably Japan’s most famous CEO, has never done a merger close to that size. It was the biggest takeover ever undertaken by a Japanese company. Risky or game changing - and for Weber, who orchestrated the deal, extremely ambitious. “At first glance, it would look like something that is incredibly risky.” “It was extremely shocking,” Karen Andersen, an analyst at investment research firm Morningstar, recalled. Moody’s and S&P Global slashed Takeda’s credit rating as a result. Takeda will also borrow some $30 billion. Takeda is paying nearly 60% more than Shire’s stock price at the time of Weber’s first bid. Industry watchers were stunned when, a few months later, Weber clinched the deal at $62 billion. Some members of the company’s founding family - who are still big shareholders - were queasy when Weber made the announcement. Takeda has roots in Japan that go back 250 years. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |